APACRM is the conference forum whose 8th meeting is summarized in this paper. It is presented as a venue for open discussions, case studies, and panel discussions on regenerative medicine regulation.
First-pass extracted concept
Asia Partnership Conference of Regenerative Medicine
Candidate: concept label1 source documents5 linked claims
Live refresh every 5sNext refresh in 5s
Aliases
8th APACRM, APACRM
Extracted Explainers
What the tool is doing
Resources required
What problem it solves
Evidence Snippets
Supporting Sources
Linked Claims
The 8th APACRM was held to advance regulatory harmonization for regenerative medicine products across Asia.
Quoted textsource-backed
The 8th Asia Partnership Conference of Regenerative Medicine (APACRM) was held in a hybrid format-both in person and online-on April 24, 2025, to advance regulatory harmonization for regenerative medicine products across Asia.
This paper summarizes the proceedings of the 8th APACRM to facilitate future dialogue and promote dissemination of regulatory information across the field.
Quoted textsource-backed
This paper summarizes the proceedings of the 8th APACRM to facilitate future dialogue and promote the dissemination of regulatory information across the field.
The conference program included presentations by industry experts and panel discussions with representatives from regulatory agencies.
Quoted textsource-backed
The program included presentations by industry experts and panel discussions with representatives from regulatory agencies.
Understanding domestic regulatory guidelines and their underlying rationales within each country and region is a crucial first step toward harmonized regulation.
Quoted textsource-backed
Understanding the domestic regulatory guidelines and their underlying rationales within each country and region represents a crucial first step toward achieving harmonized regulation.
The 8th APACRM included discussions and case studies on QbD in gene therapy manufacturing, non-clinical evaluation of AAV-based gene therapy products, the product lifecycle and regulatory landscape of AAV gene therapies, and post-launch regulatory requirements for regenerative medical products.
Quoted textsource-backed
The 8th APACRM featured open discussions and case study presentations addressing the Quality by Design (QbD) approach in gene therapy manufacturing, non-clinical evaluation of adeno-associated virus (AAV)-based gene therapy products, the product lifecycle and regulatory landscape of AAV gene therapies, and post-launch regulatory requirements for regenerative medical products.